Pharmacological Investigations for Elucidating Molecular Mechanism of Lallemantia Royleana and Myrica Nagi in Experimental Model of Hepatotoxicity

Abstract

Liver is second largest organ in human body which plays a major role in metabolism. newlineImpairment of liver leads to serious health consequences and in the majority of cases it is life newlinethreatening. Currently, available conventional options for hepatic diseases have certain newlinelimitations of their own, and options from medicinal plants with potent hepatoprotective newlineactivities are being searched to meet the need. Herbal medicines are growing exponentially due newlineto the decreased incidence of the adverse drug reaction and economic burden of modern system newlineof medicine. Phenolic and flavonoids are responsible for antioxidant and hepatoprotective action newlineand reduce liver associated complications. Natural drugs derived from medicinal plants sources newlinedue to better tolerance and minimum adverse drug reactions, as well as they have wide range of newlinebiological activity, higher safety of margin and lesser cost. In present study M. nagi leaves and l newlineroyelena seeds were screened for pharmacognostical, phytochemical profile and pharmacological newlineactivities. Results of quantitative phytochemical analysis TPC and TFC results showed that ethyl newlineacetate extract of M. nagi (74.21 ± 0.14 and 96.62 ± 0.10 respectively) leaves and methanolic newlineextract of L. royelena seeds (83.85 ± 0.21 and 78.21 ± 0.16 respectively) having higher flavonoid newlineand phenolic content while the aqueous extract of L. royelena and M. nagi showed least TPC newline(25.06 ± 0.24 and 9.80 ± 0.10) and TFC content (22.05 ± 0.25 and 18.18 ± 0.23). FTIR newlinespectroscopy analysis confirmed the presence of alcohols, alkenes, Phenols, aromatic carboxylic newlineacid, esters, aliphatic amines, and primary secondary amines in the M. nagi leaves and L newlineroyelena seed. newline